PMS Registry
Company Name
Bayer Taiwan Co., Ltd.
Protocol Number
Title of Study
AURIGA / An observationAl stUdy pRogram to InvestiGate the effectiveness of intravitreal Aflibercept in diabetic macular edema and/or macular edema secondary to retinal vein occlusion in a real world setting.
Primary Objective
AURIGA is designed to collect data from routine clinical practice on intravitreal aflibercept in the treatment of visual impairment due to DME or macular edema seconday to RVO.
The primary objective of this OS is to evaluate the effectiveness of intravitreal aflibercept in 4 cohorts (with/without prior treatment in DME ormacular edema secondary to RVO patients) in each of the participating countries
Number of Sites
Period of Study
From:2018 Q4 to:2020 Q2
Number of Patients
Taiwan greater or equal to 410人人
IRB Approval Date
TPVGH 25Jun2018
NTUH 10Sep2018
CCH 20Sep2018
CMH Pending
MMH 20Sep2018
KHVGH 04Oct2018
TSGH Pending
NCKUH 05Oct2018
CMUH 12Oct2018
SKH 21Sep2018
KMUH Pending
Publication Plan / Date